Bausch Health Companies Inc. (BHC.TO)
| Previous Close | 10.27 |
| Open | 10.28 |
| Bid | 10.19 x 0 |
| Ask | 10.20 x 0 |
| Day's Range | 10.18 - 10.44 |
| 52 Week Range | 7.56 - 15.43 |
| Volume | |
| Avg. Volume | 403,150 |
| Market Cap | 3.741B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 10, 2010 |
| 1y Target Est | N/A |
- ACCESSWIRE
Bausch Health Announces First Quarter 2024 Results
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basis Year-over-year revenue growth in all segments on both a Reported and Organic1 Basis GAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 Million ...
- ACCESSWIRE
Bausch Health to Announce First-Quarter 2024 Results on May 2
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST ...
- ACCESSWIRE
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that the U.S. Court of Appeals for the Federal Circuit in the matter of Salix Pharmaceuticals, ...
